stockrowStandard BioTools Inc.
LAB Healthcare Medical Devices
Standard BioTools Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.3 million, down 6.24% from fiscal 2024.
- Revenue
- −0.85%
- EPS
- +138.1%
- Free cash flow
- +73.3%
- Total debt
- +0.33%
Quarter to September 2026, against a year earlier
Follow LAB
Alert me
Standard BioTools Inc. (LAB) EV/Sales
As of 6 November 2026, Standard BioTools Inc. (LAB) trades at a EV/Sales of −2.5×. Over the past ten years it has ranged from −2.6× (August 2026) to 11.5× (March 2015); the current reading is higher than 1% of that period. That is below the Medical Devices industry median of 2.8× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.6× | (1.22%) |
| FY2024 | 3.6× | 453.26% |
| FY2023 | 0.7× | 7,036.96% |
| FY2022 | 0.0× | (99.65%) |
| FY2021 | 2.6× | (14.63%) |
| FY2020 | 3.0× | 55.73% |
| FY2019 | 2.0× | (47.18%) |
| FY2018 | 3.7× | 11.86% |
| FY2017 | 3.3× | (2.76%) |
| FY2016 | 3.4× | (4.74%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | −1.9× | — |
| Jun 2026 | −1.8× | — |
| Mar 2026 | −1.1× | — |
| Dec 2025 | 3.6× | (27.23%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LAB Standard BioTools Inc. | −2.5× |
| RXST RxSight, Inc. compare | −0.4× |
| TMCI Treace Medical Concepts, Inc. compare | 1.4× |
| INFU InfuSystems Holdings, Inc. compare | 2.1× |
| ELMD Electromed, Inc. compare | 2.8× |
| TLSI TriSalus Life Sciences, Inc. compare | 3.9× |
| CLPT ClearPoint Neuro, Inc. compare | 6.0× |
| PROF Profound Medical compare | 10.0× |
| QSI Quantum-Si Incorporated compare | 147× |
| Medical Devices industry median | 2.8× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)